neurology

News

Concept of memory loss and brain aging due to dementia and alzheimer's disease as a medical icon with fall trees shaped as a human head losing leaves with 3D illustration elements.

Biogen abandons tau antibody for Alzheimer's after phase 2 m...

Biogen has four other Alzheimer's candidates in its clinical pipeline behind recently-approved Aduhelm, but one of them – anti-tau antibody gosuranemab – has just been canned.

News

Consumer group seeks resignation of top FDA staffers over Ad...

With the first patient set to receive Biogen's new Alzheimer's drug Aduhelm in Rhode Island today, US consumer advocacy organisation Public Citizen is deeply unhappy about the FDA's approva

News

Closeup of X-ray photography of human brain

And then there were three: another FDA adcomm member quits o...

The fallout over the FDA's decision to approved Biogen's Alzheimer's therapy Aduhelm continues to be felt, with a third member of its advisory committee resigning in protest.

News

Double resignation over Aduhelm approval depletes FDA's CNS ...

Two members of an FDA advisory committee have now resigned in protest over Monday's approval

News

Close Up Of Senior Man Suffering With Parkinsons Diesease

Bayer's two-pronged cell/gene therapy assault on Parkinson's...

Bayer subsidiary BlueRock Therapeutics has dosed the first Parkinson's disease patient in a phase 1 trial of its cell-based therapy DA01, which aims to replenish the neurons lost in people

News

Will Gottlieb follow up on Trump's promise of a bonfire of regulations?

Aduhelm approval could signal new era for CNS drugs; analyst...

The unexpected approval and lofty pricing of Biogen's Alzheimer's therapy Aduhelm is clearly the biopharma event of the year so far, but what are the broader implications for the industry a

Biogen abandons tau antibody for Alzheimer's after phase 2 m...

Consumer group seeks resignation of top FDA staffers over Ad...

And then there were three: another FDA adcomm member quits o...

Double resignation over Aduhelm approval depletes FDA's CNS ...

Bayer's two-pronged cell/gene therapy assault on Parkinson's...

Aduhelm approval could signal new era for CNS drugs; analyst...

Biogen, Denali pull Parkinson's drug after failed trial

Discover a new era of healthcare panel engagement: Grounded ...

neurology

Editor's Picks